Director, Medical Affairs
IlluminaFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Candidates must possess deep domain knowledge of the Diagnostic Services industry, with a strong preference for Molecular Diagnostic experience. Experience selling Oncology-based tests and services into the Pathology and/or Oncology clinical communities is required, along with experience in complex selling environments. Demonstrated success in recruiting, hiring, developing, and retaining talent is essential, as is the ability to prioritize and align organizational goals, enable innovation, and develop cross-functional relationships.
The Business Development Director will lead and drive the MRD sales strategy and efforts across the MRD Clinical Account Executive team and broader oncology sales team. This role involves managing business results, sales activities, and strategic collaborations, while making day-to-day decisions to manage the MRD business function, including resource deployment and cost allocation. Responsibilities include developing comprehensive business plans, assessing market intelligence to solve challenges, aligning initiatives with strategic objectives, and maintaining key customer relationships. The director will also plan and conduct sales meetings, maintain product and market knowledge, identify contracting opportunities, oversee CRM management for the MRD team, develop account executive skills, support internal sales-facing initiatives, collaborate with sales leaders on hiring and training, and drive sales enablement through CRM and data analytics.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.